XML 65 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BeiGene Agreement - Narrative (Details) - Collaboration and License Agreement - USD ($)
12 Months Ended
Dec. 31, 2018
Jan. 07, 2018
Dec. 31, 2019
Dec. 31, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Up-front fee received   $ 10,000,000.0    
Termination of contract, period after first commercial sale of product   10 years    
Period required for notice of termination of contract   60 days    
Revenue from performance obligations satisfied during reporting period     $ 309,000  
Revenue from performance obligation expected to be earned   $ 123,000,000.0    
Licenses of Intellectual Property        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue from performance obligation earned     0 $ 9,500,000
Manufacturing Supply Services        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue from performance obligations satisfied during reporting period     300,000 100,000
Revenue from performance obligation earned $ 500,000   3,000,000.0 400,000
Increase (Decrease) in Contract with Customer, Liability     (3,300,000) (500,000)
Cost-sharing receivable     400,000  
Milestone Payments        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue from performance obligation earned       $ 3,000,000.0
Revenue from performance obligation expected to be earned     5,000,000.0  
Royalties        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue     $ 0